Clinical trials located in

Torquay

Torquay city is located in United Kingdom. Currently, 7 clinical trials are being conducted in this city.

Torquay, nestled along the English Riviera in Devon, UK, is renowned for its stunning coastline and maritime climate. This seaside town boasts a rich history, with evidence of human settlement dating back 40,000 years. Famous for its picturesque beaches, Torquay also played a pivotal role in the evolution of the English Riviera’s tourism industry. It is the birthplace of the world-famous author Agatha Christie, adding a literary charm to its cultural heritage. The town’s prehistoric caves, Kents Cavern, are a significant archaeological site, revealing insights into early human life.

  • CT-EU-00041883

    Research on new medicine for advanced or metastatic lung cancer

    This study investigates a new medicine called JDQ443’s ability to combat advanced non-small cell lung cancer. It involves two groups based on their PD-L1 levels and mutations KRAS G12C. The study has two parts (called cohorts), each involving different people. The study is carried out in stages called ‘cycles’ which last for 21 days each. During the study, assessments will be conducted to evaluate the medicine’s effectiveness, and health monitoring will be implemented. This involves measuring factors such as the duration until disease progression and the length of survival post-treatment initiation.

    • Opnurasib/JDQ-443
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study on durvalumab with oleclumab or monalizumab for lung cancer

    This is a study about two new treatments for a type of lung cancer called Non-small Cell Lung Cancer. This study is for adults with Stage III unresectable non-small cell lung cancer who’ve already had chemoradiation. It’s testing the effects of durvalumab combined with either oleclumab or monalizumab. The treatments are given through IV on a 28-day cycle for up to 12 months. The main goal is to see if these drug combinations can stop cancer from progressing and help patients live longer.

    • Oleclumab
    • Monalizumab
    • Durvalumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.